Pharmaceutical Sales Strategy: When the Decision Moves Away From the Prescriber

Most pharmaceutical sales strategy still starts in the same place: rank prescribers by how much they prescribe in the therapy area, assign the top ones to reps, and set a target for how often each should be seen. Reach and frequency, by decile.

That model assumes the person the rep is visiting is the person who decides. For a growing share of prescriptions, that is only partly true. The physician still writes the prescription, but which drug is on the formulary, which one the health system's protocol puts first, and which one the patient's insurer will cover without a fight have often been settled before the rep walks in.

So there are two shrinkages happening at once. Reps get fewer minutes with prescribers, which is widely discussed. And prescribers often have less freedom to act on what they hear, which is discussed much less and matters more for strategy. This guide is about the second one: how to find where the decision is actually made, and how to build targeting, channels and the role of each field team around it.

The access problem is two problems

The first problem is time. Many physicians see fewer reps than they used to, for shorter visits, and more of the relationship runs through remote calls, email and medical information requests. We covered what that does to how a field force should be measured, and why it makes the quality of each conversation the main lever left, in sales force effectiveness.

The second problem is discretion. A physician working inside a health system may be choosing between the two drugs on the system's formulary, following a treatment pathway written by a committee, and prescribing what the patient's plan covers without prior authorisation. A rep can deliver a flawless call to that physician and change nothing, because the decision the call was aimed at is no longer theirs alone.

A perfect call to a physician who cannot act on it is still a wasted call. Before asking how to get more time with prescribers, ask how much of the decision they still hold.

Map where the decision is made

The first piece of strategy work is a decision map: for this product, in this market, which decisions determine whether a suitable patient ends up on it, and who makes each one. The answer differs by product, therapy area and country, which is exactly why it has to be mapped rather than assumed.

Decision	Made by	Your side
Covered, on what terms?	Payers	Market access
On the formulary?	Health-system pharmacy committee	Key account managers, medical
Where in the pathway?	Clinical leads who write protocols	MSLs, key account managers
Right for this patient?	The prescriber	Sales reps
Started and continued?	Patient, nurses, pharmacists	Patient support

Read down the right-hand column and a common problem shows up. Many organisations put most of their people in the fourth row, because that is where the field force has always been, while the decisions in the first three rows are made by a handful of people who get far less attention.

The map does not mean prescriber calls stop mattering. For a product with open formulary access and no restrictive pathway, the prescriber holds most of the decision and the classic model works well. The point is to know which situation each product is in, account by account, instead of running the same model everywhere.

Segment on freedom to act, not only volume

Prescriber deciles rank physicians by their past prescribing in the therapy area. That is a reasonable measure of potential and a poor measure of whether a visit can change anything. A high-volume prescriber inside a system whose formulary excludes your product is high potential and close to zero opportunity for a rep.

A more useful segmentation crosses two questions.

• Potential: how many of this prescriber's patients fit the label?
• Freedom to act: if persuaded, can they actually prescribe it, given the formulary, protocols and coverage they work under?

	Free to act	Constrained
High potential	Classic rep priority: see often, sharpest message	Work the system: key accounts, formulary, protocol
Low potential	Efficient channels: remote, digital, samples	Low priority, unless they influence others

The constrained, high-potential box is where strategies most often go wrong. The instinct is to visit those prescribers more, because their numbers look attractive. The better move is usually to work on whatever is constraining them, which means a different team talking to different people.

There is a third dimension the two boxes miss: influence. The physician who sits on the pharmacy and therapeutics committee, or who wrote the local treatment pathway, may prescribe modestly themselves and still shape the prescribing of everyone around them. Identify these people explicitly. They are rarely visible in prescription data, and they are usually the right audience for medical rather than promotional conversations.

Give each channel one job

Once the decisions are mapped and the targets segmented, decide what each channel is for. A frequent mistake is using the most expensive channel, an in-person rep visit, to do work a cheaper one could do as well.

• In-person rep visits: for conversations that can change a decision — a new indication, new data, a real objection to work through. Not for reminders.
• Remote calls and digital channels: for reminders, information requests, and prescribers who prefer them. Useful, but rarely where minds change.
• Key account management: for health systems and integrated networks, where the formulary and pathway decisions sit. This is account selling with a committee, much closer to target account selling than to a detail call.
• Medical science liaisons: for scientific exchange with clinical experts and protocol authors, kept clearly separate from promotion.
• Market access: for payers and coverage.

The strategic question for each target is which of these channels it needs, and in what order. For a constrained account, a successful formulary review may be what makes every later rep visit worth having.

The line the rep can't cross, and the handoff that matters

Promotional conversations have strict limits. In the United States, for example, promotion has to stay within the approved labelling and present benefits and risks with fair balance. Questions about uses outside the label cannot be answered by a rep. They are routed to medical affairs, where medical science liaisons can respond in a non-promotional way, typically when the physician has asked unprompted. The rules differ by country, and every company has its own standard operating procedures, which are the ones that apply.

Most companies treat this boundary as a compliance matter, and it is. It is also a strategic one, for a reason that is easy to miss: in a constrained market, many of the most valuable questions are exactly the ones a rep cannot answer. A clinical lead deciding where a drug sits in a pathway wants to discuss the evidence in depth, including the populations and comparisons the label does not cover. That conversation belongs to medical.

So the strategy has to include the handoff, not only the line:

1. The rep recognises the question as one they cannot answer and says so plainly, without sounding evasive.
2. The rep routes it properly through the company's medical information process, rather than letting it drop.
3. Medical responds, and the rep does not try to fill the gap themselves later.

A rep who handles the first step badly loses the physician's trust. A rep who handles it well signals that the company takes the evidence seriously, which supports every later conversation. We describe how the off-label redirect plays out in an actual call on the pharmaceutical sales page.

Where strategy meets the call

Every part of this ends in a short conversation. The decision map tells a rep which prescribers can act. Segmentation tells them who to see. The channel plan tells them what the visit is for. None of it helps if the ninety seconds in front of the physician are spent reading a detail aid, or if the off-label question at the end is fumbled.

Those moments are rehearsable, and they are rarely rehearsed. The main pharma call types are worth practising before they happen: the compressed detail with one key message, the formulary conversation with a pharmacy director, the side-effect question from a physician whose patient had a bad experience, and the off-label redirect under pressure. If the strategy has moved your team toward key accounts, add the committee conversation, which reps who came up through prescriber calls have usually practised least. Our guide to medical sales training courses covers what a broader training programme should include.

Where our tool fits

We build an AI practice tool, so read this with that in mind.

SalesArmor lets pharma reps rehearse these calls against a realistic AI physician or pharmacy director before the real visit, including the two-minute detail and the off-label redirect, with the call scored afterwards. The scenarios are on our pharmaceutical sales page. It is practice, not compliance review: your own medical and legal teams still approve what reps say.

Common questions about pharmaceutical sales strategy

What is a pharmaceutical sales strategy? It is the plan for how a company brings a medicine to the patients it can help: which decisions determine whether suitable patients receive it, who makes each one, which customers to prioritise, which channels and teams to use for each, and what every interaction is meant to achieve. Traditionally it centred on prescriber reach and frequency; increasingly it also has to cover formularies, pathways and payers.

Why are traditional pharma sales models struggling? Two reasons. Reps get less time with physicians, and many physicians have less freedom to choose because formularies, health-system protocols and insurance coverage now settle part of the decision in advance. A model built on visiting high-prescribing physicians often targets a decision that is no longer fully theirs.

How should pharma companies segment and target prescribers? By more than prescribing volume. Combine potential (how many patients fit the label) with freedom to act (whether formulary, protocols and coverage let them prescribe it), and add influence, such as membership of a pharmacy committee or authorship of local pathways. High-potential but constrained prescribers usually need work on the system around them, not more visits.

What is the difference between a pharmaceutical sales rep and an MSL? Sales reps have promotional conversations within the approved labelling. Medical science liaisons sit in medical affairs and have non-promotional scientific exchange with clinical experts, often in response to questions physicians raise themselves. Questions outside the label are routed from reps to medical, under each company's own procedures.

What can a pharmaceutical sales rep not say? In general, reps must keep promotion within the approved labelling, present benefits and risks with fair balance, and not discuss unapproved uses. When a physician asks about an off-label use, the rep should say they cannot discuss it and route the question to medical information. The exact rules vary by country and company.

What is key account management in pharma? It is account-level selling to health systems, integrated networks and hospital groups, where decisions about formularies and treatment pathways are made by committees rather than individual prescribers. It looks more like complex B2B account selling than a traditional detail call, and it usually involves medical and market access colleagues as well.

How do pharma reps make the most of short HCP calls? By having one clear message per visit, knowing beforehand whether this physician can act on it, and rehearsing the short version until it sounds natural. The questions most likely to come up, including side effects and off-label requests, should be practised before the visit rather than improvised.

How is pharmaceutical sales strategy different from medical device sales strategy? Pharma decisions often run through formularies, payers and prescriber choice across many patients, while device decisions are typically made through hospital purchasing and value analysis committees for capital or procedure-based products. Both have moved decisions away from the individual clinician, which is why both need account-level strategy as well as clinician calls.

A note on sources

This guide publishes no figures on how much time physicians give reps, how many physicians restrict access, field force sizes or the share of prescriptions governed by formularies and pathways. Those numbers vary by country, therapy area and year, and the widely circulated ones come from vendor and consultancy surveys with methods we could not check.

The description of promotional rules and the rep–medical boundary is general and based on publicly available regulatory principles, mainly in the United States. It is not legal advice; practice differs by country and by company. The decision map, the potential-by-freedom segmentation and the argument that the medical handoff is a strategic as well as a compliance question are ours.